Medivance

Medivance

Medivance, Inc develops, manufactures, and sells temperature management products to hospitals worldwide The company’s flagship product,.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
-investor

€0.0

round
investor investor investor investor investor

€0.0

round
N/A

€0.0

round
investor investor investor investor investor

€0.0

round
N/A

€0.0

round

$250m

Valuation: $250m

Acquisition
Total Funding000k
Notes (0)
More about Medivance
Made with AI
Edit

Medivance, Inc. operated as a medical technology firm focused on the emerging field of Targeted Temperature Management (TTM). Founded in 1998 by Robert Kline, who also served as CEO, the company established itself as a market leader in therapeutic hypothermia. Headquartered in Louisville, Colorado, Medivance developed and commercialized the Arctic Sun™ Temperature Management System, a non-invasive technology designed to precisely regulate a patient's core body temperature.

The company's business model revolved around the sale of its proprietary medical devices and the associated single-use disposable products to hospitals and critical care units. Its primary clients were clinicians in intensive care settings treating patients for a variety of conditions where temperature control is crucial for improved outcomes, such as after cardiac arrest. The technology addressed a significant unmet need in a market segment experiencing double-digit growth. Over its history as a private entity, Medivance successfully raised $59.2 million in capital from institutional investors, including Camden Partners and Cross Atlantic Capital Partners, to fund its growth and product development.

Medivance's flagship product, the Arctic Sun™ system, consists of a control module and single-use ArcticGel™ Pads that adhere to the patient's skin. This system enables highly efficient heat transfer by circulating temperature-controlled water through the pads, allowing clinicians to rapidly and precisely manage patient temperature between 32 and 38.5 degrees Celsius. Key features included pre-programmable protocols, automated temperature feedback and adjustments, and the ability to download treatment data for analysis. A significant milestone was the 510(k) clearance from the FDA for its next-generation Arctic Sun® 5000 model in 2010. A major corporate achievement occurred in October 2011, when C.R. Bard, Inc. announced its acquisition of Medivance for approximately $250 million, integrating the company into its Bard Medical division to complement its critical care product line.

Keywords: Medivance, Targeted Temperature Management, therapeutic hypothermia, Arctic Sun, patient cooling, Robert Kline, non-invasive thermoregulation, critical care medical devices, C.R. Bard, patient temperature control, ArcticGel Pads, medical device acquisition, neuroprotection, post-cardiac arrest care, fever control, normothermia, critical care technology, temperature modulation, medical heat transfer, Louisville Colorado medical technology

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo